Fulgent Genetics (FLGT) Cash from Financing Activities (2016 - 2026)

Fulgent Genetics has reported Cash from Financing Activities for 11 years, with the latest figure at -$24.2 million in Q2 2026.

• Quarterly Cash from Financing Activities fell 818.31% year-over-year to -$24.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$70.0 million (down 376.31% YoY) and the FY2025 annual result came in at -$14.8 million, down 205.12% from the prior year.
• Cash from Financing Activities rose to -$24.2 million in Q2 2026 per FLGT's latest filing, from -$44.8 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at -$327000.0 in Q4 2024 and troughed at -$44.8 million in Q1 2026.
• A 5-year average of -$11.9 million and a median of -$3.6 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities plunged 1086.42% in 2022, then jumped 98.74% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$29.6 million in 2022, then rose by 12.31% to -$26.0 million in 2023, then surged by 98.74% to -$327000.0 in 2024, then slumped by 63.3% to -$534000.0 in 2025, then plunged by 4436.52% to -$24.2 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$24.2 million, -$44.8 million, and -$534000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.